CN101417119A - The medical composition and packing and the anserine that are used for reducing fast the uric acid of blood are used for reducing fast the purposes of blood uric acid - Google Patents
The medical composition and packing and the anserine that are used for reducing fast the uric acid of blood are used for reducing fast the purposes of blood uric acid Download PDFInfo
- Publication number
- CN101417119A CN101417119A CNA2008101711024A CN200810171102A CN101417119A CN 101417119 A CN101417119 A CN 101417119A CN A2008101711024 A CNA2008101711024 A CN A2008101711024A CN 200810171102 A CN200810171102 A CN 200810171102A CN 101417119 A CN101417119 A CN 101417119A
- Authority
- CN
- China
- Prior art keywords
- anserine
- blood
- uric acid
- amount
- medical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The present invention relates to a kind of medical composition that is used for reducing fast the uric acid content of individual blood, it comprises the anserine (anserine) to the amount of about 600mg greater than 50mg.The invention further relates to a kind of packing, it comprises medical composition and indication with anserine compositions is thrown with individual to provide each dosage greater than label and/or the inset of 50mg to the anserine of the amount of about 600mg.In addition, the present invention relates to anserine and making in order to the purposes in the medicine of the uric acid content in the quick reduction individual blood, wherein said medicine comprises the anserine to the amount of about 600mg greater than 50mg.
Description
Technical field
The present invention relates to throw with greater than 50mg to the anserine of the amount of about 600mg so that reduce uric acid content in the individual blood fast.
Background technology
Uric acid is the end product of purine metabolism in the human body.Uric acid content in the blood changes with the balance between purine decomposition and the urate excretion speed.Over several years, hyperuricemia has been associated with gout or has thought that hyperuricemia is identical with gout, but has differentiated the labelling of uric acid as a large amount of metabolism and hemodynamic abnormalities at present.Metabolic arthritis content in the blood brings out gout, and usually with relevant such as the symptom of muscle spasm, local swelling, inflammation, arthralgia, muscle fatigue, constriction and myocardial infarction.
Used multiple commercialization medicine to treat gout, for example benzbromarone (Benzbromarone, URINORM), probenecid (Probenecid), allopurinol (Allopurinol), bucolome (Bucolome), cinchophen (Cinchophan) and colchicine (Colchicine).These medicines pass through (for example) inhibition uric acid and form, and remove excessive uric acid, act on kidney to help to eliminate uric acid, and the activity that the inhibition xanthine oxidase is converted into xanthine uric acid works with quickening urate excretion.Yet known these medicines have hepatotoxicity, and cause multiple side effect, such as urinary stone, gastrointestinal obstruction, jaundice and anemia.Do not report these medicines and can reduce uric acid content in the individual blood fast.
More known dipeptides are applicable to the uric acid content that reduces in the blood.For instance, ROC (Taiwan) patent I280136 number (No. the 092114798th, ROC (Taiwan) patent application case) discloses a kind of compositions that is used to reduce uric acid in the individual body, one or more dipeptides of being made up of histidine or its functional equivalent and alanine or its functional equivalent that it comprises effective dose.The exemplary dipeptides of mentioning in the ROC patent comprises carnosine (carnosine), anserine, decarboxylation carnosine (carcinine) and Serpentis carnosine (ophidine).Only teaching oral administration every day and compositions are providing about 8mg to about 50mg for it, and preferably about 10mg is to the dipeptides of the amount of about 45mg, but do not disclose or proposition can reduce any approach of the uric acid content in the individual blood fast by throwing and dipeptides.
Anserine (β-alanyl-1-methyl-L-histidine) is high stability dipeptides, and it has about 7.1 pK value, and is kept perfectly under low pH value (＜3.0).Anserine is natural to be present in vertebrate skeletal muscle tissue and the cerebral tissue, and form (referring to Tuo Kaqifukaya (Tolkachevskaya), NF.1929. physiology's The Chemicals (Z Physiol Chem.) 185:28-32.) by the peptide bond between Beta-alanine and the 1-methyl-L-histidine.1938, the report anserine was a kind of ideal physiology acid-base buffer agent.Because its physiology soda acid buffer capacity, anserine can effectively be eliminated the lipid peroxidation that promotes by the pH value that changes biosystem.For the acidemia individuality of suffering from gout, throw with the anserine that serves as acid-base buffer agent and help to adjust the pH value of blood, and help reducing the uric acid content in the blood.Should be appreciated that, in the quick muscle fiber buffer capacity 40% provided by the dipeptides that is in the mobile phase, and the remainder of quick muscle fiber buffer capacity is provided (referring to Bei Te-Smith (Bate-Smith) by the myogen that is in basically in the immobile phase, EC.1938, " accurate muscle buffering: protein, phosphate and carnosine (The buffering ofmuscle in rigour:protein; phosphate and carnosine.), " physiology's magazine (J Physiol.) 92:336-43.).This shows in the myocyte of highly structural, and local soda acid gradient is by the buffering inhibitory action of the buffering assosting effect of mobile phase and immobile phase and form.
In addition, anserine has various anti-oxidation characteristics and suitable radical scavenger or the metal-chelator done.The individuality of suffering from inflammation for a long time has higher in vivo number of free radical usually.Throw with the anserine that serves as radical scavenger and help eliminating free radical.
Anserine also can effectively suppress by ferrum; hemoglobin; the lipid peroxidation that lipid peroxidation enzyme and singlet oxygen promote is (referring to Ba Bizha also husband MA people such as (Babizhayev MA); 1994; " L carnosine (β-alanyl-L-histidine) and decarboxylation carnosine (β-alanyl histamine) serve as the Natural antioxidant (L-carnosine (beta-alanyl-L-histidine) and carcinine (beta-alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid-peroxidaseactivities) with hydroxyl radical free radical purification and lipid peroxidation enzymatic activity; " journal of biological chemistry (Biochem J.) 304 (Pt2): 509-516 and Koln R. people such as (Kohen R.); 1988; periodical (the Proc Natl Acad Sci USA.) 85 (9) of " being present in the carnosine in muscle and the brain; the antioxidant activity of homocarnosine and anserine (Antioxidantactivity of carnosine; homocarnosine; and anserine present in muscle and brain), " institute of NAS: 3175-3179.).
In addition, anserine can improve the in vivo oxidation stress that is caused by fatigue, and strengthens biological intravital oxygen-derived free radicals absorbability.Anserine also can serve as the precursor of the mediator in the maincenter histaminergic nerve system.Metabolism via histidine contained in the anserine, anserine can effectively be adjusted the histamine concentration among the central nervous system, reduce the concentration of cortisol in the blood and make tired the alleviation (referring to A Wei W people such as (Aoi W.), 2006, " motion and functional food (Exercise andfunctional foods.); " No. the 6th, 680,294, threpsology's magazine (Nutr J.) 5:15-22 and United States Patent (USP)).
Yet, do not report the marketed drugs that comprises anserine that is used for the treatment of gout and have the effect of the uric acid content in the quick reduction individual blood.
To developing a kind of uric acid content that can reduce fast in the individual blood, still there are needs in the new drug for the treatment of gout thus and alleviating the symptom relevant with metabolic arthritis content in the blood.
Summary of the invention
The present inventor is unexpected to be found, throws with each dosage and can reduce uric acid content in the individual blood greater than 50mg fast to the anserine of the amount of about 600mg.
Therefore, the present invention relates to a kind of medical composition that is used for reducing fast the uric acid content of individual blood, it comprises the anserine to the amount of about 600mg greater than 50mg.
The invention further relates to a kind of comprise medical composition of the present invention and indication with compositions throw with individual with provide each dosage greater than 50mg to the label of the anserine of the amount of about 600mg and/or the packing of package insert.
In addition, wood invention relates to a kind of method that is used for reducing fast the uric acid content of individual blood, and it comprises and will throw and individuality to the anserine of the amount of about 600mg greater than 50mg.
In addition, the present invention relates to anserine and making in order to the purposes in the medicine of the uric acid content in the quick reduction individual blood, wherein said medicine comprises the anserine to the amount of about 600mg greater than 50mg.
Description of drawings
Fig. 1 show oral administration and anserine to the influence of the uric acid content in the blood.
The specific embodiment
In first aspect, the invention provides a kind of medical composition that is used for reducing fast the uric acid content of individual blood, it comprises the anserine to the amount of about 600mg greater than 50mg.Medical composition of the present invention can reduce the uric acid content in the individual blood fast, treats the relevant symptom of metabolic arthritis content in gout and/or improvement and the blood thus.
In second aspect, the invention provides a kind of packing, it comprises medical composition of the present invention and indication throws with individual compositions to provide each dosage greater than label and/or the package insert of 50mg to the anserine of the amount of about 600mg.Packing of the present invention is applicable to the uric acid content in the quick reduction individual blood, treats the relevant symptom of metabolic arthritis content in gout and/or improvement and the blood thus.
In the third aspect, the invention provides a kind of method that is used for reducing fast the uric acid content of individual blood, it comprises and will throw and individuality to the anserine of the amount of about 600mg greater than 50mg.Method of the present invention can reduce the uric acid content in the individual blood fast, treats the relevant symptom of metabolic arthritis content in gout and/or improvement and the blood thus.
In fourth aspect, the invention provides the purposes of a kind of anserine in making the medicine that can reduce the uric acid content in the individual blood fast, wherein said medicine comprises the anserine to the amount of about 600mg greater than 50mg.Described medicine can reduce the uric acid content in the individual blood fast, treats the relevant symptom of metabolic arthritis content in gout and/or improvement and the blood thus.
Anserine can be naturally occurring anserine or synthetic anserine.In the present invention, with anserine with each dosage greater than 50mg to about 600mg, preferably about 100mg is to about 500mg, more preferably from about amount throwing and the individuality of 150mg to 250mg, to reach the effect of the uric acid content in the quick reduction individual blood.
In the application's case, term " reduce uric acid content in the blood fast " and mean throw with anserine 1 hour in, the reduction amount of the uric acid content in the individual blood is about 0.5 to about 4mg/dL.Term " individuality " is meant and is preferably the mankind by mammal.In addition, term " symptom relevant with metabolic arthritis content " is meant (for example) muscle spasm, local swelling, inflammation, arthralgia, muscle fatigue, constriction, myocardial infarction or its combination.
Medical composition of the present invention and medicine can prepare by known any conventional method in this technology.Except that the active ingredient anserine, medical composition of the present invention and medicine also can comprise pharmaceutically or the physiology goes up acceptable excipient.Suitable pharmaceutically acceptable excipient includes, but is not limited to dextrin-maltose, lactose, sucrose, mannitol, starch, microcrystalline Cellulose, carboxymethyl cellulose, Pulvis Talci and magnesium stearate.
Medical composition of the present invention and medicine are adjustable to be appropriate dosage forms, such as tablet, powder, granule, capsule, liquid and suspension, for being used for various dosing ways.Medical composition of the present invention and medicine can via any suitable pathways, preferably via the oral cavity or non-through the intestinal approach throw with.
Any known package and printing process all can be used for preparing packing of the present invention.
Example
With reference to following example, the present invention will become apparent, and described example is entirely exemplary and does not use with the of the present invention category of restriction described in claims.
Example 1
Anserine (GL biochemistry corporation,Ltd. (GL Biochem Ltd.), Chinese Shanghai) and dextrin-maltose are filled in the gelatine capsule (gross weight is 400mg), and capsule comprises the 50mg anserine.Suffer from the individual every day that has metabolic arthritis content in gout and the blood and take 3 capsules (the anserine total amount is 150mg) twice, with once taking 5 capsules (the anserine total amount is 250mg) on the same day, the anserine accumulated dose that take therefore individual every day is 550mg.(a kind of quick serum-uric acid test strip, (Apex Biotechnology Co., Inc.), (Hsinchu Taiwan), ROC) monitors Hsin-chu uric acid content in the blood in summit Bioisystech Co., Ltd by UroSpeed.The results are shown in the table 1, and be further illustrated among Fig. 1.
Table 1: oral administration and anserine be the reduction of uric acid content in the blood after 1 hour
As table 1 and shown in Figure 1, take comprise anserine capsule after 1 hour in the blood reduction scope of uric acid content be 0.9mg/dL to 1.5mg/dL.Take the 150mg anserine after 1 hour at 10:35, the uric acid content in the blood reduces 1.5mg/dL.After individuality stock cattle flesh noodles at noon, the uric acid content in the individual blood increases to 11.9mg/dL.Take the 150mg anserine after 1 hour at 13:15, the uric acid content in the individual blood reduces 0.9mg/dL.Take the 250mg anserine after 1 hour at 17:17, the uric acid content in the individual blood reduces 1.3mg/dL.Digital proof throwing that provides in the table 1 and anserine can reduce the uric acid content in the individual blood fast in 1 hour.
Example 2
In this oral administration test, test 15 voluntary one-tenth individual humans (9 male and 6 women of 28 years old to 53 years old) of suffering from chronic hyperuricemia.Described individuality stops its normal Drug therapy at least 3 days.Mean urinary acid content in the described individual blood is greater than 9.3mg/dL.Described individuality is divided into 5 groups at random, and each group comprises 3 individualities, takes the anserine of following dosage respectively: 50mg, 100mg, 150mg, 200mg and 250mg.After 1 hour, measure the uric acid content in the individual blood.Find that the uric acid content in its blood reduces 1.1mg/dL to 1.3mg/dL.In 5 groups, the reduction of taking uric acid content in the blood of group of 150mg anserine is the most obvious.The results are shown in the table 2.
Table 2: the anserine of oral administration and various dosage after 1 hour to the influence of the uric acid content in the blood
Claims (14)
1. medical composition that is used for reducing fast the uric acid content of individual blood, it comprises the anserine to the amount of about 600mg greater than 50mg.
2. medical composition as claimed in claim 1, it comprises the anserine of about 100mg to the amount of about 400mg.
3. medical composition as claimed in claim 2, it comprises the anserine of the amount of about 150mg to 250mg.
4. as the described medical composition of arbitrary claim in the claim 1 to 3, its be applicable to the treatment gout and/or alleviate with blood in the relevant symptom of metabolic arthritis content.
5. medical composition as claimed in claim 4, wherein said symptom are selected from muscle spasm, local swelling, inflammation, arthralgia, muscle fatigue, constriction, myocardial infarction and its combination.
6. packing, it comprises:
The medical composition that comprises anserine; With
Indication throws with individual described compositions providing each dosage greater than the anserine of 50mg to the amount of about 600mg, so that treat gout and/or alleviate the label and/or the inset of the symptom relevant with metabolic arthritis content in the blood.
7. packing as claimed in claim 6, wherein said label and/or the indication of described inset throw with individual described compositions so that about 100mg to be provided the anserine to the amount of about 500mg.
8. packing as claimed in claim 7, wherein said label and/or the indication of described inset throw with individual described compositions so that about 150mg to be provided the anserine to the amount of about 250mg.
9. packing as claimed in claim 6, wherein said symptom are selected from muscle spasm, local swelling, inflammation, arthralgia, muscle fatigue, constriction, myocardial infarction and its combination.
10. an anserine is being made in order to the purposes in the medicine of the uric acid content in the quick reduction individual blood, and wherein said medicine comprises the anserine to the amount of about 600mg greater than 50mg.
11. purposes as claimed in claim 10, wherein said medicine comprise the anserine of about 100mg to the amount of about 400mg.
12. purposes as claimed in claim 11, wherein said medicine comprise the anserine of about 150mg to the amount of about 250mg.
13. purposes as claimed in claim 10, wherein said medicine be applicable to the treatment gout and/or alleviate with blood in the relevant symptom of metabolic arthritis content.
14. purposes as claimed in claim 13, wherein said symptom are selected from muscle spasm, local swelling, inflammation, arthralgia, muscle fatigue, constriction, myocardial infarction and its combination.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007274191A JP2009102248A (en) | 2007-10-22 | 2007-10-22 | Pharmaceutical composition for rapidly decreasing uric acid in blood and package, and use of anserine for rapidly decreasing uric acid in blood |
| JP2007274191 | 2007-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101417119A true CN101417119A (en) | 2009-04-29 |
Family
ID=40628245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008101711024A Pending CN101417119A (en) | 2007-10-22 | 2008-10-15 | The medical composition and packing and the anserine that are used for reducing fast the uric acid of blood are used for reducing fast the purposes of blood uric acid |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2009102248A (en) |
| CN (1) | CN101417119A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103719990A (en) * | 2013-12-17 | 2014-04-16 | 浙江现代中药与天然药物研究院有限公司 | Functional beverage containing spirulina and skipjack bone extractive |
| CN105784873A (en) * | 2016-05-06 | 2016-07-20 | 常熟市医学检验所 | High-uric-acid renal injury early diagnosis marker based on metabonomics and application thereof |
| CN106474454A (en) * | 2016-12-07 | 2017-03-08 | 谢灵均 | A kind of compositionss and its purposes reducing uric acid, treatment or prevention gout |
| CN108524910A (en) * | 2018-06-03 | 2018-09-14 | 马南行 | A kind of composition and preparation method thereof for treating gout |
| CN111228459A (en) * | 2019-07-17 | 2020-06-05 | 江苏西宏生物医药有限公司 | Composition for treating and preventing gout |
| CN115066273A (en) * | 2019-12-27 | 2022-09-16 | 三得利控股株式会社 | Composition comprising cyclic dipeptide, purine nucleoside and/or amino acid and chicken extract, method for producing same and use of cyclic dipeptide, purine nucleoside and/or amino acid and chicken extract |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110038119A (en) * | 2019-04-28 | 2019-07-23 | 杭州泽健医药科技有限公司 | A kind of pharmaceutical composition with anti-trioxypurine and antifatigue effect |
| CN113321699B (en) * | 2021-05-08 | 2024-07-19 | 武汉桀升生物科技有限公司 | Preparation method and application of anserine cholate |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI280136B (en) * | 2003-05-30 | 2007-05-01 | Lytone Enterprise Inc | Composition containing dipeptide of histidine and alanine for reducing uric acid |
-
2007
- 2007-10-22 JP JP2007274191A patent/JP2009102248A/en active Pending
-
2008
- 2008-10-15 CN CNA2008101711024A patent/CN101417119A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103719990A (en) * | 2013-12-17 | 2014-04-16 | 浙江现代中药与天然药物研究院有限公司 | Functional beverage containing spirulina and skipjack bone extractive |
| CN103719990B (en) * | 2013-12-17 | 2018-10-12 | 浙江现代中药与天然药物研究院有限公司 | A kind of functional beverage containing spirulina and stripped tuna bone extract |
| CN105784873A (en) * | 2016-05-06 | 2016-07-20 | 常熟市医学检验所 | High-uric-acid renal injury early diagnosis marker based on metabonomics and application thereof |
| CN105784873B (en) * | 2016-05-06 | 2017-10-13 | 常熟市医学检验所 | High lithemia injury of kidney early diagnosis marker and its application based on metabolism group |
| CN106474454A (en) * | 2016-12-07 | 2017-03-08 | 谢灵均 | A kind of compositionss and its purposes reducing uric acid, treatment or prevention gout |
| CN106474454B (en) * | 2016-12-07 | 2017-12-08 | 谢灵均 | A kind of composition and its reduction uric acid, the purposes for treating or preventing gout |
| CN108524910A (en) * | 2018-06-03 | 2018-09-14 | 马南行 | A kind of composition and preparation method thereof for treating gout |
| CN111228459A (en) * | 2019-07-17 | 2020-06-05 | 江苏西宏生物医药有限公司 | Composition for treating and preventing gout |
| CN111228459B (en) * | 2019-07-17 | 2023-10-27 | 江苏西宏生物医药有限公司 | Composition for treating and preventing gout |
| CN115066273A (en) * | 2019-12-27 | 2022-09-16 | 三得利控股株式会社 | Composition comprising cyclic dipeptide, purine nucleoside and/or amino acid and chicken extract, method for producing same and use of cyclic dipeptide, purine nucleoside and/or amino acid and chicken extract |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009102248A (en) | 2009-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101417119A (en) | The medical composition and packing and the anserine that are used for reducing fast the uric acid of blood are used for reducing fast the purposes of blood uric acid | |
| CA2499199C (en) | Leucine-enriched nutritional compositions | |
| CN111050764A (en) | β -hydroxybutyrate and butanediol S enantiomers and methods of use thereof | |
| ES2330111T3 (en) | COMPOSITION AND METHOD TO FACILITATE BONE HEALING. | |
| SG191369A1 (en) | Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate | |
| WO2008122190A1 (en) | The composition comprising l-carnitine or derivatives thereof and its use | |
| WO2012145369A1 (en) | Compositions and methods for nutritional supplementation | |
| KR20180094517A (en) | Garlic composition | |
| CN101998859B (en) | Pharmaceutical composition for preventing dysbiosis associated with enteral administration of antibiotics | |
| EP2247290A1 (en) | Polyphenols for the treatment of cartilage disorders | |
| EP3677273B1 (en) | Bacteroides cellulosityticus for use in preventing and/or treating atherosclerosis and obesity | |
| CN116348104A (en) | Compositions and methods for cartilage degeneration using a combination of oleuropein and quercetin | |
| CN105233288A (en) | Pharmaceutical composition for treatment or prevention of obesity-related hypertension and usage of pharmaceutical composition for treatment or prevention of obesity-related hypertension | |
| JP2014507437A (en) | Composition for enhancing joint and / or posture stability | |
| CA2591416A1 (en) | Medicinal composition containing fbpase inhibitor | |
| US7166309B2 (en) | Nutritional composition and method of inhibiting smooth muscle cell contraction thereof | |
| CN111228459B (en) | Composition for treating and preventing gout | |
| EP2052735B1 (en) | Pharmaceutical composition and kit comprising anserine for rapidly reducing uric acid in blood | |
| RU2335927C2 (en) | Nutrient compositions enriched with leucine | |
| CN102283832B (en) | Medicinal composition for preventing or treating hypertensive obese patient and application thereof | |
| JP2008509877A (en) | Pharmaceutical formulation for suppressing cardiovascular disease, usually containing vitamin C, magnesium, green tea extract | |
| US20230398104A1 (en) | Compositions containing nicotinamide and vitamin b6 and methods of using such compositions for rehabilitation | |
| TWI643632B (en) | Extract of asparagus officinales leaf, the extraction method and the use thereof | |
| Majeed et al. | A new class of phytonutrients for body weight management | |
| CN105520947B (en) | A kind of pharmaceutical composition with weight losing function containing Glucosamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20090429 |